They will have easy access during their peak working hours for customer support and technical assistance. This is another significant step in continuing to expand on our abilities to better serve our clients.
Los Gatos, CA (PRWEB) September 9, 2009
New England Peptide, LLC, (NEP) today announced the opening of its West Coast development office, which will allow the company to provide more hands-on support and service to new and existing customers in the western United States. The office, located in the San Francisco Bay area, will be overseen by John Phipps, a leading peptide chemist and entrepreneur who joined NEP in March.
"We are very excited to expand NEP's presence on the West Coast and to provide a more direct connection with our customers there," said NEP Chief Executive Officer Dave Robinson. "In fact, the opening of the new office is a direct response to the needs of our customers, who are turning to NEP for increasingly complex peptide and antibody solutions, many with commercial end points. As NEP moves toward clinical grade products, it's more important than ever to provide real-time support to our clients."
Robinson said Phipps, with his scientific and entrepreneurial background, was the ideal person to lead NEP's West Coast operations. In 2001, Phipps founded Global Peptide Services, a Colorado-based custom peptide synthesis company that produced molecules for biological research and development.
"The opening of the California office will be a significant benefit to our customers on the West Coast," said Phipps. "They will have easy access during their peak working hours for customer support and technical assistance. This is another significant step in continuing to expand on our abilities to better serve our clients."
Phipps said that NEP would be very active in west coast biotechnology and pharmaceutical networks. The company recently joined BayBio, the trade organization that represents the Bay Area Biotech cluster.
The opening of the California office is the latest in a series of exciting developments for NEP, the Massachusetts-based designer and producer of custom peptides and polyclonal antibodies for drug, vaccine and diagnostic discovery organizations worldwide. In July, NEP introduced the peptide industry's first flash purification system, which more rapidly and cost-effectively prepares research grade peptides for its customer use worldwide. NEP's proprietary process, named FlashPure™, removes non-peptide contaminants from unpurified peptide arrays, or "crude" peptide libraries, which gives the array peptides improved solubility and more predictable activity in the laboratory.
In addition to Phipps, over the past year NEP has attracted some of the peptide industry's top talent to its team. In December, NEP named award winning peptide research expert Dr. Robert Hammer as its vice president of chemical development. Hammer and new SAB members Dr. Robert Hodges, led NEP's transition to the use of alternative solvents amid the recent global shortage of acetonitrile.
Dr. Vincent Bille, Dr. Tomi Sawyer, Dr. Victor Hruby are the other members of the SAB, which was formed in October. Another member of the SAB, Dr. Ved Srivastava, left the board in February to become NEP's vice president for research production.
"The talent we have been able to assemble over the past several months has been remarkable," said Robinson. "With a growing team and the ability to quickly service customers across the nation, we are excited for the future of NEP."
About New England Peptide (http://www.newenglandpeptide.com)
New England Peptide, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides' inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use.
# # #